istock-485508035-alexandrumagurean

alexandrumagurean / iStockphoto.com

13 September 2018Big Pharma

LSIPR webinar: HGF delves into personalised healthcare patents

Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

22 March 2018 Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.

LSIPR webinar: HGF on doctrine of equivalence evolution

16 October 2018 The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

More on this story

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

22 March 2018 Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.

LSIPR webinar: HGF on doctrine of equivalence evolution

16 October 2018 The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

More on this story

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

22 March 2018 Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.

LSIPR webinar: HGF on doctrine of equivalence evolution

16 October 2018 The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.

More features

President Trump 2.0: Five major areas to watch

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug